1. Scrip
  2. >>Therapy Areas
  3. >>Cardiovascular

Adeona partners Intrexon in stock-for-tech deal for pulmonary arterial hypertension

 
• By Nancy Faigen

Adeona Pharmaceuticals, a development firm that does not have its own in-house R&D, has entered into a global collaboration with the synthetic biology company Intrexon whereby Adeona hopes to develop and commercialise a DNA-based treatment for pulmonary arterial hypertension (PAH). Adeona is 'buying' access to Intrexon's technology with its stock.

Adeona Pharmaceuticals, a development firm that does not have its own in-house R&D, has entered into a global collaboration with the synthetic biology company Intrexon whereby Adeona hopes to develop and commercialise a DNA-based treatment for pulmonary arterial hypertension (PAH). Adeona is 'buying' access to Intrexon's technology with its stock.

The deal structure, under which Intrexon will initially receive 9.995% of Adeona's stock (worth around $2.2 million on 21 November...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

Novartis Upbeat Even With Entresto Expiry Looming

 
• By Kevin Grogan

Swiss major confident that new oncology drugs will fill revenue gap.

AstraZeneca’s Amyloidosis Drug Fails In Phase III But Subgroup Hopes Persist

 
• By Andrew McConaghie

Anselamimab was expected to complement Alexion's portfolio of amyloid therapies, but regulators will have to be convinced of its benefits to a patient subgroup in the CARES trial.

Bayer’s Kerendia Gains Blockbuster Indication For Heart Failure

 
• By Joseph Haas

New US approval in heart failure with preserved or mildly reduced ejection fraction should add to Kerendia’s earning power on top of chronic kidney disease indication.

Phase III Success For AstraZeneca’s $5bn Hypertension Hope Baxdrostat

 
• By Andrew McConaghie

Rivals Mineralys could be first to file but AstraZeneca is banking on its cardiovascular market know-how to lead the emerging class.

More from Therapeutic Category

Insmed’s New R&D Site Focused On ‘Synthetic Rescue’

 
• By Andrew McConaghie

A new small-molecule approach to turning on beneficial genes to counteract disease-causing mutations is being pioneered by Insmed’s UK-based scientists.

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By Vibha Ravi

As AI-driven firms including Insilico, big pharmas J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?

BMS/Pfizer To Sell Discounted Eliquis Direct – And Other Drugmakers May Follow Suit

 
• By Alaric DeArment

Analysts see the new strategy as a way to address pressure from the Trump administration’s most favored nation drug pricing proposals.